Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10203454 | 1.00 | MEN1 (0.32) | MEN1USP2GAAKMT2A | |
| SCHEMBL10203447 | 1.00 | MEN1 (0.32) | MEN1USP2GAAKMT2A | |
| SCHEMBL10190116 | 0.87 | PHGDH (0.32) | MEN1USP2GAAKMT2A | |
| SCHEMBL26243347 | 0.87 | GNAI3 (0.32) | — | |
| Hydrochloric Acid SCHEMBL25388926 | 0.85 | GNAI3 (0.35) | — | |
| SCHEMBL8067419 | 0.81 | OPRM1 (0.41) | — | |
| Hydrochloric Acid SCHEMBL17185017 | 0.81 | OPRM1 (0.38) | — | |
| SCHEMBL23268045 | 0.80 | PHGDH (0.33) | MEN1KMT2A | |
| SCHEMBL602814 | 0.79 | CHRM4 (0.43) | — | |
| SCHEMBL602815 | 0.79 | CHRM4 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426443-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2013-04-23 | — | — | US | disclosed |
| US-20120316202-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED | 2012-12-13 | — | — | US | disclosed |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2012-12-13 | — | — | US | disclosed |
| US-20120309789-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED | 2012-12-06 | — | — | US | disclosed |
| US-8299257-B2 | Compounds which have activity at M1receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8278328-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20110207777-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | TELECOM IP LIMITED | 2011-08-25 | — | — | US | disclosed |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100210687-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | Glaxo Group Limited a corporation | 2010-08-12 | — | — | US | disclosed |
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | COOPER DAVID GWYN | 2010-07-29 | — | — | US | disclosed |
| WO-2008119713-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | MEN1 1081/4885USP2 4745/4885GAA 290/4885 |
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | MEN1 339/4885USP2 4592/4885GAA 735/4885 |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | MEN1 1081/4885USP2 4745/4885GAA 290/4885 |
| US-20100210687-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | MEN1 945/4885USP2 4857/4885GAA 896/4885 |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | MEN1 945/4885USP2 4857/4885GAA 896/4885 |
| US-20120316202-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | MEN1 1923/4885USP2 4635/4885GAA 361/4885 |
| US-20110207777-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | MEN1 1088/4885USP2 4749/4885GAA 288/4885 |
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | MEN1 1309/4885USP2 4743/4885GAA 302/4885 |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | CHRM1, CHRM2, CHRM5 | MEN1 945/4885USP2 4857/4885GAA 896/4885 |
| US-20120309789-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | MEN1 2181/4885USP2 4624/4885GAA 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.